Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of health care-associated infections. Vancomycin remains an acceptable treatment option. There has been a welcome increase in the number of agents available for the treatment of MRSA infection. These drugs have certain differentiating attributes and may offer some advantages over vancomycin, but they also have significant limitations. These agents provide some alternative when no other options are available.

Surgical wound dehiscence complicated by methicillin-resistant Staphylococcus aureus infection in a diabetic patient with femorotibial vascular bypass occlusion

“…Then, at home, daptomycin was switched to teicoplanin, another first-line anti-MRSA agent, to ensure the therapeutic continuity and avoid relapses. 15 Both physical examination (colour, temperature of the skin and palpation of peripheral pulse) and colour Doppler sonography of the lower limbs were periodically performed to warrant the good outcome of the vascular bypass over time.…”

Effect of Dalbavancin on Staphylococcal Biofilms When Administered Alone or in Combination With Biofilm-Detaching Compounds

“…Given that some of these antibiotics have been shown to be able to penetrate through thick biofilms, their lack of inhibition could be due to a low metabolic activity of biofilm-embedded cells, which is known to decrease their susceptibility to antibiotics (Jefferson et al, 2005;Jacqueline and Caillon, 2014;Lopatkin et al, 2019). Thus, our data suggest that dalbavancin may act on established biofilms more efficiently than linezolid and vancomycin, which are among the most common antibiotics clinically administered for biofilm infections caused by S. aureus and S. epidermidis (Choo and Chambers, 2016). This may be facilitated by its mechanism of action, because this antibiotic not only inhibits bacterial cell wall synthesis but has also an ability to bind to bacterial membranes (Chen et al, 2013).…”

In Vitro Daptomycin and Linezolid Susceptibility Profiles of Enterococcus faecium and Enterococcus faecalis Strains Isolated from Blood Cultures

“…Bütün izolatlar daptomisin ve linezolide karşı duyarlı olarak saptanmış-tır (16,17) . E. faecalis için daptomisin MİK aralığı 0.006-1 µg/ml, MİK 50 0.5 µg/ml ve MİK 90 1 µg/ ml; linezolid MİK aralığı 0.25-2 µg/ml, MİK 50 0.75 µg/ml ve MİK 90 1.5 µg/ml olarak saptan-mıştır.…”

“…Yükselmiş vankomisin MİK değerlerine sahip olan MRSA izolatlarında daptomisin kullanımı-nın, vankomisin kullanımına avantajlı olduğu olgu kontrol çalışmaları ile gösterilmiştir (16) .…”